Phospholipase D (PLD) plays important roles in cellular responses to tissue injury that are critical to acute inflammatory diseases, such as the acute respiratory distress syndrome (ARDS). We investigated the expression of PLD isoforms and related phospholipid phosphatases in patients with ARDS, and their roles in a murine model of self-limited acute lung injury (ALI). Gene expression microarray analysis on whole blood obtained from patients that met clinical criteria for ARDS and clinically matched controls (non-ARDS) demonstrated that PLD1 gene expression was increased in patients with ARDS relative to non-ARDS and correlated with survival. In contrast, PLD2 expression was associated with mortality. In a murine model of self-resolving ALI, lung Pld1 expression increased and Pld2 expression decreased 24 h after intrabronchial acid. Total lung PLD activity was increased 24 h after injury. Pld1 −/− mice demonstrated impaired alveolar barrier function and increased tissue injury relative to WT and Pld2 −/− , whereas Pld2 −/− mice demonstrated increased recruitment of neutrophils and macrophages, and decreased tissue injury. Isoformspecific PLD inhibitors mirrored the results with isoform-specific Pld-KO mice. PLD1 gene expression knockdown in human leukocytes was associated with decreased phagocytosis by neutrophils, whereas reactive oxygen species production and phagocytosis decreased in M2-macrophages.
the inflammatory milieu can potentiate tissue injury and cause human disease, such as ARDS. 4 Phospholipase D (PLD) is necessary for cellular responses to tissue injury and microbial invasion, 5 including leukocyte adhesion, 6 and phagocytosis. 7 Cellular models have shown that PLD1 is highly expressed in leukocytes and regulates several aspects of acute inflammatory responses, including oxidative burst. 8 PLD2 plays important roles in regulating phagocytosis and cell replication. 9 Both PLD1 and PLD2 are necessary for leukocyte chemotaxis. 10 An experimental model of acute pancreatic injury has shown that PLD1 and PLD2 regulate leukocyte recruitment to inflamed tissue and edema formation. 11 In a sepsis model with secondary lung injury, PLD2 deficiency afforded lung protection and increased survival. 12 Here, we examined PLD involvement in host responses to the important clinical problem of ARDS.
The enzymatically active isoforms of the PLD superfamily, PLD1 and PLD2, hydrolyze phosphatidylcholine to generate choline and phosphatidic acid (PA). The PA generated via PLD activity can play multiple roles in cellular function. 13 PA can function in signal transduction events, such as activation of a phosphoinositide kinase, or as a lipid-binding partner to several proteins. In addition, PA production is important in vesicle trafficking, endocytosis, and secretion.
PA can also be further converted by PA phosphatases to diacylglycerol, which also signals for cellular processes important to inflammation and tissue repair. 14 Apart from its metabolic functions, PLD can also regulate select cellular functions through direct interactions with other proteins. 7 Results presented here show that PLD1 expression increased in ARDS patients and was associated with survival. In a murine model of self-resolving ALI, PLD1 gene expression in injured lungs increased, whereas PLD1 deficiency worsened ALI severity by alveolar barrier disruption and decreased macrophage phagocytosis. In contrast, PLD2 expression was associated with mortality in ARDS patients, and PLD2 expression decreased in murine self-resolving ALI. PLD2 deficiency lessened ALI severity, and was associated with increased recruitment of macrophages with enhanced phagocytosis and decreased neutrophil production of reactive oxygen species (ROS). Together, these findings have uncovered counterregulation by PLD isoforms that influence the nature and severity of tissue injury.
MATERIALS AND METHODS

Registry of Critical Illness
Details of the Research Registry and Human Sample Repository for the Study of the Biology of Critical Illness, abbreviated as the Registry of Critical Illness (RoCI), have been previously published. 15 The Patients are classified by the treating intensive care physician team as sepsis, and sepsis with ARDS (sepsis/ARDS). Sepsis was identified according to the 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference guidelines. 16 ARDS was defined according to American-European Consensus Conference on ARDS guidelines. 17 All ARDS patients were endotracheally intubated and mechanically ventilated using a low tidal volume ventilation strategy according to ARDSNet protocol. 18 The following parameters were collected for each patient for further analyses: age, race, gender, length of hospital stay, APACHE II score, in-hospital mortality, 28-day mortality and overall mortality. APACHE II was calculated on intensive care unit (ICU) admission day for every patient, 19 and mortality was assessed using the Partners Health Care Research Patient Data Registry (RPDR) linking deaths to the Social Security Death Index (SSDI).
Human microarray datasets
Peripheral blood with corresponding demographic and clinical information was obtained from adult patients were obtained from subjects enrolled in the RoCI at the Brigham and Women's Hospital ICU. 15 Samples were also obtained from adult patients in the University of Pittsburgh Medical Center ICU, 20 and pediatric patients (< 10 years old) admitted to the Cincinnati Children's Hospital pediatric ICU. 21 
Microarray preprocessing, normalization, and analysis
All preprocessing and analysis of linear correlation between gene expression levels, ARDS diagnosis, and 28-day survival after adjustment for age, sex, race, and age were performed in R 3.2/Bioconductor. 22, 23 To evaluate the concordance of gene expression patterns across different microarray platforms, we mapped each microarray probe to its genomic coordinates on the UCSC Human Genome version 18 (hg18) using the R/Bioconductor biomaRt package. 24, 25 We next matched probes to those on different platforms using the nearest genomic start position and filtering out probes that were not represented across all platforms. 25, 26 The number of probes in the pooled dataset carried forward for normalization was 18,694.
We used the R package, CONOR, to perform distance weighted discrimination cross-platform normalization, to account for differences in probe length, probe type, number of probes, labeling methods, and detection methods. 27 PLD genes are expressed as PLD1 and PLD2 in humans, and Pld1, Pld2 in murine datasets. 28 and Dr. Yasunori Kanaho (Department of Physiological Chemistry, University of Tsukuba, Tsukuba, Japan). 29 The Pld1 −/− and Pld2 −/− mice were backcrossed with C57bl/6 mice for > 7 generations. 29, 30 Mice were fed a standard diet (Laboratory Rodent Diet 5001; PMI Nutrition International, St. Louis, MO) containing 4.5% total fat with 0.3% -3 fatty acids and <0.02% C20:4 and were provided water ad libitum.
Mice
Murine model of acid-induced acute lung injury
All mice were maintained under specific pathogen-free conditions. All studies were reviewed and approved by the Harvard Medical Area standing committee on animals (protocol no. 03618). Mice were anesthetized with i.p. injections of ketamine (100 mg/kg body wt; Phoenix Scientific, St. Joseph, MO) and xylazine (10 mg/kg body wt; Phoenix Scientific). As in Abdulnour et al., 31 hydrochloric acid (0.1 N HCl, pH 1.5, 50 L, endotoxin free; Sigma-Aldrich, St Louis, MO) was instilled selectively into the left mainstem bronchus via a 24-G angiocatheter inserted intratracheally. was added to reach ∼1 mg/mL solutions. Lysis buffer composition for Western blots and enzyme assays was: 50 mM HEPES, pH 7.2, 100 M Na 3 VO 4 , 0.1% Triton X-100 and 1 mg/mL each of protease inhibitors (aprotonin and leupeptin). Lung tissue was ground with a micromotorized pestle homogenizer, followed by sonication (10 s) on ice. Samples were spun for 5 min at 250 × g on a refrigerated centrifuge (4 • C) to remove debris and supernatants were taken for further analyses
Preparation
Gene expression measurement by qRT-PCR
Reverse transcription coupled to qPCR was performed following published technical details. 32 
Phospholipase activity assay
The measurement of total PLD activity was reported previously. 6, 33 Briefly, the assay was performed in liposomes of 1,2-dioctanoylsn-glycero 
Bronchoalveolar lavage
At timed intervals, mice were euthanized and the trachea exposed. A 20-gauge angiocatheter was inserted into the trachea and the lungs were lavaged with 2 separate 1 mL volumes of ice-cold PBS with 0.6 mM EDTA. The bronchoalveolar lavage (BAL) fluid was pooled, centrifuged at 500 × g for 5 min at 4 • C to pellet the cell fraction. The cell pellet was suspended in cold PBS, and the supernatant was used for albumin, protein, and cytokine analysis. BAL neutrophil count was highest at 24 h after ALI (Supplemental Fig. S1 and, 31 therefore that time point was used for determinations after ALI.
Assessment of vascular leakage after pharmacologic isoform-specific PLD inhibition
Evans blue dye (EBD, 40 mL/kg) was injected into the tail vein of mice 30 min before termination of the experiment to assess vascular leak. In brief, lungs were lavaged and perfused free of blood with DPBS before being excised en bloc. The left lungs were dried in an oven (56 • C) for 48 h and weighed. The lungs were then homogenized in DPBS (500 L), incubated with 2 vol formamide (18 h, 56 • C), and centrifuged at 5000 × g for 30 min, and the optical density of the supernatant was determined by spectrophotometry at 620 nm.
Extravasated EBD in lung homogenates ( g EBD per lung) was calculated with an EBD standard curve. To inhibit PLD isoforms, animals were treated with a specific PLD1 inhibitor (VU0155069), 35 PLD2 inhibitor (VU0364739), 29 or vehicle (saline in 10% vol/vol DMSO), given by intraperitoneal injections on days −3, −2, −1, and 0 (1 h prior to ALI, 10 mg/kg in 10% DMSO).
FACS analysis and cell sorting
BAL cells were obtained after centrifugation of pooled BAL fluid, and the cell pellet was stained with fluorochrome-labelled antibodies to obtain a leukocyte differential as in Abdulnour et al. 36 
Determination of bioactive molecule levels in BALF
Select cytokines were measured in aliquots of pooled BALF using a bead-based immunoassay as per the manufacturer's instructions (LEGENDPlex by Biolegend, San Diego, CA). 
Histopathology
Gene silencing
Neutrophil superoxide release
Neutrophil ROS production, specifically, superoxide anion release was measured by the reduction of cytochrome c with several neutrophil agonists as indicated, with PMA (50 ng/mL) as the positive control and SOD was used to stop the reactions.
Leukocyte chemotaxis
Chemotaxis against IL-8 (10 nM; neutrophils) or MCP-1 (30 nM; macrophages) was measured in Transwell (5 m diameter pore for neutrophil, 8 m diameter pore for macrophage) for specified lengths of time; cells migrated at the bottom of the wells were stained and counted. Averages from 7 fields were plotted.
Macrophage phagocytosis
Macrophage phagocytosis was determined using fluorescent-labeled GFP zymosan A (Saccharomyces cerevisiae) (Invitrogen, Carlsbad, CA) as in Ref. 37 . Briefly, the particles were opsonized at 37 • C for 1 h using the zymosan A BioParticles opsonizing reagent (derived from highly purified rabbit polyclonal IgG antibodies) (Invitrogen) and were applied to 1 × 10 7 cells such that there were approximately 20 zymosan particles per each cell. After application of GFP-Zymosan, the 6-well plates containing the cells were centrifuged at 800xg for 5 min and then were incubated at 37 • C for 15 min. Fluorescent-labeled zymosan particles ingested by macrophages were counted manually under the microscope in 5 different fields, and the averages and SEM calculated.
Neutrophil-extracellular traps
To detect NETs in the airway, cell-free supernatant of BAL fluid was used to quantify extracellular DNA citrullinated histone H3, which is a well-established marker of NETs. QuantIt Picogreen DNA quantification assay was used for the quantification of DNA. Rabbit anticitrullinated histone H3 (citH3) (ab5103; Abcam, Cambridge, MA, USA) was used to perform immunoblots.
Statistical analysis
All data are expressed as means ± SEM. Comparisons between groups were conducted using ANOVA and Student's t-test as appropriate. A level of P ≤ 0.05 was considered to indicate statistical significance.
Statistics were performed using Graphpad Prism 6.0 for Windows (San Diego, CA).
RESULTS
PLD genes are regulated in patients with ARDS
To determine gene expression profiles in ARDS, microarray analysis was performed on peripheral blood obtained from patients with ARDS (N = 19) and from clinically matched patients without ARDS (Non-ARDS, N = 29) enrolled in a RoCI (Table 1 ). In addition to PLD1 and PLD2, the expression profile of phospholipid phosphatases (PLPP), a family of genes that includes PA phosphatases, was determined (Sup- 
PLD1 and PLD2 are differentially expressed in human peripheral blood from ARDS survivors
To examine the relationship between gene expression and ARDS outcome, ARDS survivors were identified in the BWH RoCI, and peripheral blood gene expression at presentation was compared with ARDS nonsurvivors. PLD1 and PLD2 expression were changed 1.2 and −1.0 fold (log2) respectively in ARDS survivors (Fig. 1D ). Of note, PLPP2
TA B L E 1 RoCI demographics
expression was also increased in ARDS survivors (1.84 log2 FC; Supplemental Fig. S2d ). Together, these results indicate differential expression of PLD1 and PLD2 genes in peripheral blood leukocytes from ARDS patients. Specifically, PLD1 expression was associated with survival, whereas PLD2 expression was associated with mortality in ARDS patients.
Pld1 and Pld2 gene expression are differentially regulated in lungs after self-limited acute tissue injury
To further characterize the roles of these phospholipases in response to acute lung injury (ALI), lung Pld1 and Pld2 gene expression was determined after sterile lung injury using a model of ARDS from gastric acid aspiration, an important clinical risk factor for ARDS (see Materials and Methods; Fig. 2A ). Pld1 and Pld2 were expressed in neutrophils, macrophages, epithelial cells, and endothelial cells, with relatively more Pld2 expression in macrophages and endothelial cells (Supplemental Fig. S3 ). Lung Pld1 expression significantly increased 2.91 fold (±0.72) relative to control (Fig. 2B) , whereas lung Pld2 expression significantly decreased 0.12 fold (±0.09; Fig. 2C ). Expression of PLPP genes was also regulated; Plpp1 and Plpp2 expression increased 12.4 fold (±1.83; Fig. 2D ) and 3.3 fold (±0.46; Fig. 2E ) in
F I G U R E 2 PLD isoforms and phospholipid phosphatase genes are differentially regulated in lungs after acute lung injury. (A) Model of selective intratracheal HCl instillation to the left lung, and tissue harvesting at 24 h. Gene expression of (B) Pld1, (C) Pld2, (D) Plpp1, (E) Plpp2, and (F) Plpp6 in control and lungs 24 h after intratracheal HCl. Gene expression is expressed in fold change relative to housekeeping gene (GAPDH, see Materials and Methods).
Results are expressed as mean ± SEM, N > 10, *P < 0.05 injured lungs relative to control. Plpp6 expression was also increased in injured lungs (Fig. 2F ).
PLD activity increases after ALI
We next examined total lung PLD activity and the relative contribu- PLD activity was significantly increased 24 h after intrabronchial HCl in WT mice (2.34 ± 0.37; Fig. 3A ). After injury, PLD activity in lungs from Pld1 −/− (1.13 ± 0.18) and Pld2 −/− (0.99 ± 0.16) also significantly increased but remained lower than lungs from WT (Fig. 3A) .
Pld1 deficiency is associated with impaired barrier function after ALI
To determine the impact of Pld isoforms on alveolar barrier function after acid-induced lung injury, levels of extravasated albumin were quantified in the alveolar compartment. Albumin concentration in BAL fluid obtained 24 h after intrabronchial acid was significantly higher in (Fig. 3C ). Selective inhibition of PLD2 did not significantly impact barrier integrity after ALI (Fig. 3C ).
Histology obtained 24 h after acid administration showed demonstrable tissue leukocyte infiltration and alveolar and interstitial edema in the left lung of WT that were in sharp contrast to the uninjured right lung (Fig. 3D ). Relative to WT mice, alveolar edema was worse in lungs from Pld1 −/− mice, and diminished in lungs from Pld2 −/− mice (Fig. 3C ).
Of interest, determination of BAL fluid cytokine levels 24 h after injury gave significantly higher levels of IL-1 and GM-CSF in Pld2 −/− mice relative to Pld1 −/− (Supplemental Fig. S4 ). IL-6 was increased in Pld2 −/− mice relative to WT and Pld1 −/− mice but statistical significance was not reached. Levels of TNF and IL-10 were not significantly different (Supplemental Fig. S4 ).
Pld2 deficiency is associated with increased leukocyte tissue infiltration after ALI
To determine the role of Pld isoforms in acute lung inflammation, cellular host responses were examined by flow cytometric analysis of total and differential leukocyte counts in BALF after intrabronchial HCl in Pld1 −/− , Pld2 −/− , and WT mice ( in Fig. 4G ) counts increased, whereas resident alveolar macrophage counts decreased 24 h after injury (rAMs; Fig. 4E ).
The difference in direction of total leukocyte responses to injury at this time point suggests Pld isoform-specific influence on neutrophil and macrophage responses (Fig. 4B) . To this end, neutrophil and alveolar macrophage subset counts were compared after lung injury between genotypes. Total leukocyte counts were significantly higher in Pld2 −/− relative to Pld1 −/− (P = 0.009) and WT (P = 0.0004; Fig. 4B ). Together, these results indicate that deficiency in Pld2 is associated with increased neutrophil and iMac recruitment to injured lung.
Specifically, deficiency in
Pld2 deficiency is associated with increased iMac-neutrophil interactions during experimental ARDS
Recruited alveolar macrophages, iMacs and ExMacs engage with neutrophils for efferocytosis. 36 To determine if Pld2 regulates cellcell interactions between macrophages and neutrophils, macrophagebound neutrophils in BALF were quantified by flow cytometry ( 74.0 ± 5.5% of iMacs, P = 0.05; Fig. 5C ). The absolute Ly6G+ exMacs counts appeared higher in Pld2 −/− relative to WT (16.3 ± 3.9 × 10 3 vs.
8.4 ± 1.7 × 10 3 cells per BALF, P = 0.08; Fig. 5D ), and the percentage of exMAcs that were Ly6G+ was very high in both genotype groups (95.1 ± 1.3 vs. 91.6 ± 2.6% of exMacs, P = 0.12; Fig. 5E ).
PLD2 silencing enhances proresolving macrophage functions
Pld2 was associated with changes in murine macrophage recruit- (Fig. 6A) . In addition, decreased PLD1 gene expression was associated with decreased phagocytosis of latex beads relative to control (2.94 ± 0.33 vs. 4.82 ± 0.37 particle per cell, P = 0.043), whereas decreased PLD2 gene expression gave the opposite response with increased phagocytosis (6.15 ± 0.64 vs. 4.82 ± 0.37 particle per cell, P = 0.006) (Fig. 6B ).
PLD2 silencing decreased ROS production
Pld2 deficiency was associated with increased neutrophil recruitment and decreased histologic injury after experimental ALI (Figs. 3 and   4 ). The impact of PLD on neutrophil chemotaxis and ROS production was determined (see S5b ). Neutrophil ROS production in response to the agonists FMLP and PMA was determined. F-MLP (50 ng/mL) and PMA (50 ng/mL) increased ROS production in control neutrophils (Fig. 6D) . PLD1 gene expression did not significantly alter ROS production to agonists. In contrast, decreased PLD2 gene expression decreased ROS production to both agonists.
DISCUSSION
Results presented herein indicate that PLD isoforms are differentially regulated after ARDS. PLD1 gene expression is upregulated in human peripheral blood from ARDS survivors, and in murine lungs after self-limited ALI. In addition, PLD1 deficiency was associated with increased alveolar barrier disruption and tissue injury, suggesting a protective role for PLD1 in ARDS. Moreover, PLD2 gene expression was associated with ARDS nonsurvivors and was down-regulated in murine lungs after self-limited ALI. Pld2 deficiency was associated with decreased tissue injury, increased recruitment of proresolving macrophages with enhanced phagocytosis, and decreased ROS production by neutrophils. Together, these findings support a pathogenic role for PLD2 that operates in opposition to PLD1 in ARDS.
PLD1 and PLD2 are the enzymatically active members of the mammalian PLD superfamily that catalyze the hydrolysis of phosphatidylcholine, the most abundant membrane phospholipid, to generate choline and PA, a second messenger signaling lipid (PA). 10 Although animal models and in vitro studies have revealed pathogenic roles for PLD1 and PLD2 in thrombotic disease, cancer, and inflammatory diseases such as sepsis, 38 potential roles in human ARDS had yet to be investigated.
Examination of a published human gene expression microarray dataset from our institution 15 has enabled here a targeted analysis of PLD and PLD-related gene expression in patients with ARDS. clearance of alveolar edema and potentiates lung injury. 43 In addition, PLD1 activation is linked to superoxide anion generation, 5 and neutrophil adhesion. 6 Therefore, the detrimental effect of Pld1 deletion is likely related to a separate process. Endothelial cells from Pld1 −/− mice demonstrate decreased integrin-dependent cell adhesion, and migration on extracellular matrices with subsequent impairments in angiogenesis. 29 In addition, PLD1 regulates beta-catenin signaling, 9 a signaling pathway important for lung epithelial repair. 44 Intrabronchial acid targets the lung epithelium, 45 and loss of PLD1 could disrupt epithelial repair and augment barrier dysfunction. In addition, the lack of impact of Pld1 −/− on in vivo cytokine release suggests a direct action on cellular responses rather than an indirect action downstream of cytokines. 36 were also increased in Pld2-deficient mice.
These macrophage subtypes participate in efferocytosis of apoptotic neutrophils for resolution of ALI, 36 and release protective cytokines such as IL-1ra, 47 and IL-10. 48 In addition, PLD2 gene knockdown was associated with increased human macrophage transmigration and phagocytosis by cells of proresolving M2 phenotype. 3 These changes in macrophage functions related to PLD2 expression were associated with increased levels of IL-1 and GM-CSF, suggesting PLD2 signaling was upstream of macrophage cytokine expression. Indeed, GM-CSF regulates efferocytosis by alveolar macrophages after lung injury, 49, 50 and IL-1 promotes CD11b Low alveolar macrophage proliferation and differentiation into CD11b High macrophages. 51 Together, these findings suggest a regulated interplay between PLD2 and select cytokines that influence macrophage functional responses. Investigation into potential roles for PLD isoform-specific interactions with PLPP6 in ALI remains to be defined.
In summary, our findings have uncovered pathogenic and protective signaling circuits centered on PLD that are isoform specific. Data from ARDS patients and a mammalian model of self-resolving ALI demonstrated that PLD1 expression was associated with protection from tissue injury and increased survival from ARDS, whereas PLD2 expression adversely impacted recruitment of proresolving macrophages and recovery from ALI. Characterization of these distinct pathways offers a potential new host-directed therapeutic approach to ARDS that emphasizes PLD signaling and actions that are isoform specific. The opposing actions of PLD1 and PLD2 provide a mechanism for host tissues to regulate the intensity of inflammation and its resolution. 
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